Matrix metalloproteinase inhibitors: Applications in oncology

Investigational New Drugs

Volumn 17, Issue 4, 1999, Pages 387-399

  Yip, Desmond ^a   Ahmad, Athar ^a   Karapetis, Christos S ^a   Hawkins, Carolyn A ^b   Harper, Peter G ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Angiogenesis; Arthritis; Cancer; Clinical trials; Collagenase; Matrix metalloproteinase inhibitors

Indexed keywords

CYTOTOXIC AGENT; GEMCITABINE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; SCLEROPROTEIN;

ARTHRALGIA; ARTHRITIS; BONE PAIN; CANCER INVASION; CLINICAL TRIAL; DRUG POTENTIATION; HUMAN; METASTASIS; MYALGIA; PANCREAS ADENOCARCINOMA; PATHOGENESIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TUMOR MODEL; TUMOR VASCULARIZATION; WOUND HEALING;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; EXTRACELLULAR MATRIX; HUMANS; METALLOENDOPEPTIDASES; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PROTEASE INHIBITORS;

EID: 0033494157     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006386406584     Document Type: Review

References (84)

1. Duffy M: The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10: 145-155, 1992
2. Murphy G, Reynolds J, Hembrey R: Metalloproteinases and cancer invasion and metastasis (letter). Int J Cancer 44: 757-760, 1989
3. Meyer T, Hart IR: Mechanisms of tumour metastasis. Eur J Cancer 34: 214-221, 1998
4. Liotta L, Tryggvason K, Garbisa S, Hart I, Foltz C, Shafie S: Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284: 67-68, 1980
5. D'Errico A, Garbisa S, Liotta L, Castronovo V, Stetler-Stevenson W, Grigioni W: Augmentation of type IV collagenase, laminin receptor and Ki67 proliferation antigen associated with human colon, gastric and breast carcinoma progression. Mod Pathol 4: 239-246, 1991
6. Garbisa S, Scagliotti G, Masiero L, Di Francesco C, Caenazzo C, Onisto M, Micela M, Stetler-Stevenson W, Liotta L: Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 52: 4548-4549, 1991
7. Engel G, Hesselmeyer K, Auer G, Backdahl M, Eriksson E, Linder S: Correlation between stromelysin 3 mRNA level and outcome of human breast cancer. Int J Cancer 58: 830-835, 1993
8. Bramhall S, Neoptolemos J, Stamp G, Lemoine N: Imbalance of expression of matrix metalloproteinase (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 182: 347-355, 1997
9. Murray G, Duncan M, O'Neil P, McKay J, Melvin W, Fothergill J: Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 185: 256-261, 1998
10. Brown P: Matrix metalloproteinases in gastrointestinal cancer. Gut 43: 161-163, 1998
11. Kugler A: Matrix metalloproteinases and their inhibitors. Antican Res 19: 1589-1592, 1999
12. Khokha R, Zimmer M, Graham S, Lala P, Waterhouse P: Suppression of invasion by inducible expression of TIMP-1 in B 16-F10 melanoma cells. J Natl Cancer Inst 84: 1017-1022, 1992
13. DeClerck Y, Perez N, Shimada H, Boone T, Langley K, Taylor S: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloprotineases. Cancer Res 52: 701-708, 1992
14. Murphy A, Unsworth E, Stetler-Stevenson W: TIMP-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 157: 351-358, 1993
15. Johnson J, Kim H, Chesler L, Bouck N, Polverini P: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 160: 194-202, 1994
16. Werb Z, Vu TH, Rinkenberger JL, Coussens LM: Matrix-degrading proteases and angiogenesis during development and tumor formation. Apmis 107: 11-18, 1999
17. Liotta L, Steeg P, Stetley-Stevenson W: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 65: 327-336, 1991
18. Foulds L: The experimental study of tumor progression. Cancer Res 14: 327-339, 1964
19. Mignatti P, Tsuboi R, Robbins E, Rifkin D: In vitro angiogenesis on the human amniotic membrane: Requirement for bFGF-induced proteinases. J Cell Biol 108: 671-682, 1989
20. Weidner N, Semple J, Welch W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive breast carcinoma. N Eng J Med 324: 1-8, 1991
21. Evans JD, Ghaneh P, Kawesha A, Neoptolemos JP: Role of matrix metalloproteinases and their inhibitors in pancreatic cancer. Digestion 58: 520-528, 1997
22. Duffy MJ, McCarthy K: Matrix metalloproteinases in cancer: prognostic markers and targets for therapy. Int J Oncol 12: 1343-1348, 1998
23. Abbas A, Lichtman A, Pober J: Cellular and Molecular Immunology: (3rd ed.) Philadelphia: WE Saunders, 1997, pp 157-159
24. Brooks PC: Role of integrins in angiogenesis. Eur J Cane 32A: 2423-2429, 1996
25. Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA: Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92: 391-400, 1998
26. Deruygina E, Bourdon M, Reisfeld R, Strongin A: Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. Cancer Res 58: 3743-3750, 1998
27. Gilles C, Bassuk J, Pulyaeva H, Sage E, Foidart J-M, Thompson E: SPARC/Osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res 58: 5529-5536, 1998
28. Brown PD, Giavazzi R: Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 6: 967-974, 1995
29. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsolti P, Scanziani E, Brown P, Giavazzi R: Inhibition of angiogenesis and murine haemangioma growth by batimastat, a synthetic inhibitor of matrix metailoproteinases. J Natl Cancer Inst 87: 293-298, 1995
30. Sternlicht M, Lochter A, Sympson C, Huey B, Rougler J, Gray J, Pinkel D, Bissell M, Werb Z: The stromal proteinase MMP3/stromelysin-l promotes mammary carcinogenesis. Cell 98: 137-146, 1999
31. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260-1270, 1997
32. Gore M, A'Hern R, Stankiewicz M, Slevin M: Tumour marker levels during marimastat therapy (letter). Lancet 348: 263-264, 1996
33. Brown PD: Clinical studies with matrix metalloproteinase inhibitors. Apmis 107: 174-180, 1999
34. Chirivi RG, Garofalo A, Crimmin MJ, Bawden LJ, Stoppacciaro A, Brown PD, Giavazzi R: Inhibition of the metastatic spread and growth of B 16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 58: 460-464, 1994
35. Watson SA, Morris TM, Parsons SL, Steele Rl, Brown PD: Therapeutic effect of the matrix metalloproteinase inhibitor, batimastat, in a human colorectal cancer ascites model. Brit J Cancer 74: 1354-1358, 1996
36. Davies B, Brown P, East N, Crimmin M, Balkwill F: A synthetic matrix metalloproteinase inhibitor decreases tumour burden and prolongs survival of mice bearing human ovarian carcinoma xenograft. Cancer Res 56: 715-720, 1993
37. Macauley V, O'Byrne K, Saunders M, Salisbury A, Long L, Gleeson F, Ganeson T, Harris A, Talbot D: Phase I study of the matrix metalloproteinase inhibitor batimastat (BE-94) in patients with malignant pleural effusions (Abstract). Br J Cancer 71: 11, 1995
38. Talbot DC, Brown PD: Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer 32A: 2528-2533, 1996
39. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ: Matrix metalloproteinase inhibitors. Invest New Drugs 15: 61-75, 1997
40. Galardy RE, Cassabonne ME, Giese C, Gilbert JH, Lapierre F, Lopez H, Schaefer ME, Stack R, Sullivan M, Summers B: Low molecular weight inhibitors in corneal ulceration. Am NY Acad Sci 732: 315-323, 1994
41. Tressler RJ, Wee J, Summers B et al.: Galardin, a potent metalloproteinase inhibitor, prolongs survival time in a B16-F10 melanoma experimental metastasis model (Abstract). Clin Exp Metastasis 12: 28, 1994
42. Millar AW, Brown PD, Moore J, Galloway WA, Cornish AG, Lenehan TJ, Lynch KP: Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Brit J Clin Pharm 45: 21-26, 1998
43. Tierney GM, Griffin NR, Stuart RC, Kasem M, Lynch KP, Lury JT, Brown PD, Millar AW, Steele RJC, Parsons SL: A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. Eur J Cancer 35: 563-568, 1999
44. Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D.: Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Can Res 4: 1101-1109, 1998
45. Steward WP: Marimastat (BB2516): current status of development. Cancer Chemotherapy & Pharmacology 43: S56-S60, 1999
46. Rasmussen HS, McCann PP: Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Thera 75: 69-75, 1997
47. Hutchinson JW, Tierney GM, Parsons SL, Davis TR: Dupuytren's disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg -British Volume 80: 907-908, 1998
48. Rasmussen H, Rugg T, Brookes C, Baillet M, Harris J: First placebo controlled safety review of marimastat: a potential new therapeutic class (Abstract). Proc Am Soc Clin Oncol 18: 193a, 1999
49. British Biotech PLC: Results of marimastat Study 128-pancreatic cancer monotherapy trial (Press release). February 1999, http://www.britishbiotech.com/news/british _biotech_news99.htm
50. Rosemurgy A, Buckels J, Charnley R, Winston R, Steward W, Staddon A, Curtis L, Rugg T, Rasmussen H: A randomized study comparing marimastat to gemcitabine as first line therapy in patients with non-resectable pancreatic cancer (Abstract). Proc Am Soc Clin Oncol 18: 261a, 1999
51. British Biotech Pie: Results of marimastat Study 145 in gastric cancer (Press release), July 1999, http://www.britishbiotech. com/news/british_biotech_news99.htm
52. Adams M, Thomas H: A phase I study of the matrix metalloproteinase inhibitor, marimastat, administered concurrently with carboplatin, to patients with relapsed ovarian cancer (Abstract). Proc Am Soc Clin One 17: 217a, 1998
53. Anderson I, Supko J, Eder J, Vasconvelles M, Shapiro G, Skarin A, Shipp M, Janicek M, Lynch C, Lopez M, Bowers M, Rasmussen H: Pilot Pharmacokinetic Study of Marimastat (MAR) in combination with carboplatin (C)/paclitaxel (T) in patients with metastatic or locally advanced inoperable non-small cell lung cancer (NSCLC) (Abstract). Proc Am Soc Clin Oncol 18: 187a, 1999
54. Jones P, Elliot M, Dobbs N, Kakkar D, Ganesan T, Harris A: Phase I/II study of combination antiangiogenesis therapy with marimastat, captopril and fragmin (Abstract). Proc Am Soc Clin Oncol 18: 447a, 1999
55. Grochow LB: Preclinical and clinical pharmacology of matrix metalloproteinase inhibitors (MMPI's) (Abstract). Ann Oncol 9 (Suppl2): 11, 1998
56. Clemens GR, Detzer K, Bomhard E, von Keutz E: Pre-clinical drug safety profile for the antimetastatic matrix metalloproteinase inhibitory agent BAY 12-9566 (Abstract). Ann Oncol 9 (Suppl 2): 74, 1998
57. Hibner B, Bull C, Flynn C, Eberwein D, Garrison T, Casazza A, Carter C, Gibson N: Activity of the matrix metalloproteinase inhibitor BAY 12-9566 against murine subcutaneous metastatic in vivo models (Abstract). Ann Oncol 9: 75, 1998
58. Flynn C, Bull C, Matherne C, Eberwein D, Gibson N, Hibner B: Anti-invasive and anti-metastatic activity of the novel MMP Inhibitor BAY 12-9566 in subcutaneous and orthotopic models using the human colon carcinoma, HCT 116 (Abstract). Ann Oncol 9 (Suppl 2): 75, 1998
59. Hirte H, Goel R, Bennett K, Elias I, Shah A, Seymour L: Phase I study of the matrix metalloproteinase inhibitor (MMPI) BAY 12-9566 in patients with advanced cancer (Abstract). Ann Oncol 9: 75, 1998
60. Goel R, Hirte H, Shah A, Major P, Waterfield S, Holohan S, Bennett K, Elias I, Seymour L: Phase I study of the metalloproteinase inhibitor Bayer 12-9566 (Abstract). Proc Am Soc Clin Oncol 17: 217a, 1998
61. Erlichman C, Adjei A, Alberts S, Sloan J, Goldberg R, Pilot H, Rubin J: Phase I study of BAY 12-9566 - a matrix metalloproteinase inhibitor (MMPI) (Abstract). Proc Am Soc Clin Oncol 17: 217a, 1998
62. Tolcher A, Rowinsky E, Rizzo J, Britten C, Siu L, Humphrey R, Smetzer L, Sorenson M, Von Hoff D, Eckhardt S: A phase I and pharmacokinetic study of the oral matric metalloproteinase inhibitor BAY 12-9566 in combination with paclitaxel and carboplatin (Abstract). Proc Am Soc Clin Oncol 18: 160a, 1999
63. Seymour L, Hirte H, Goel R, Moore M, Elias I, Kumor K, Humphrey R: Planned and completed NCIC CTG trials with bay 12-9566, a novel metalloproteinase inhibitor (MMPI) (Abstract). Ann Oncol 9: 76, 1998
64. Shalinsky D, Brekken J, Zou H, Bloom L, McDermott C, Appelt K: AG3340, a novel MMP inhibitor, has a superior therapeutic index to carboplatin in nude mice bearing chemoresistant human MV522 lung cancer tumors (Abstract). Ann Oncol 9: 73, 1998
65. Hande K, Wilding G, Ripple G, Fry J, Arzoomanian R, Dixon M, Yuen G, Collier M: A phase I study of AG3340, a matrix metalloproteinase (MMP) inhibitor, in patients having advanced cancer (Abstract). Ann Oncol 9: 74, 1998
66. Wilding G, Small E, Ripple G, Keller M, Yuen G, Collier M: Phase I study of AG3340, a matrix metalloprotease inhibitor, in combination with mitoxantrone/prednisone in patients having advanced prostate cancer (Abstract). Ann Oncol 9: 74, 1998
67. D'Olimpio J, Hande K, Collier M, Michelson G, Paradiso L, Clendeninn N: Phase I study of the matrix metalloproteinase inhibitor AG3340 in combination with paclitaxel and carboplatin for the treatment of patients with advanced solid tumors (Abstract). Proc Am Soc Clin Oncol 18: 160, 1999
68. Collier M, Shepherd F, Ahmann F, Keller M, Michelson G, Paridiso L, Clendeninn N: A novel approach to studying the efficacy of AG3340, a selective inhibitor of matrix metalloproteases (MMPs) (Abstract). Proc Am Soc Clin Oncol 18: 482a, 1999
69. Dupont E, Savard PE, Jourdain C, Juneau C, Thibodeau A, Ross N, Marenus K, Maes DH, Pelletier G, Sauder DN: Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J Cutaneous Med Surg 2: 146-152, 1998
70. Latreille J, Riviere M, Batist G, Falardeau P, Dupont E: AE-941 (Neovastat), an inhibitor of angiogenesis: Phase I/II lung cancer clinical trial results. Ann Oncol 9, 1998
71. Riveriere M, Latreille J, Farlardeau, Batist G, Dupont E: AE-941 (Neovastat), an inhibitor of angiogenesis: Phase I/II cancer clinical trial results (Abstract). Cancer Invest 17, 1999
72. Levitt NC, Eskens F, Propper DJ, Harris AL, Denis L, Ganesan TS, Mather RA, McKinley L, Planting A, Talbot DC, Van Beurden V, Van der Burg M.: A phase one pharmacokinetic study of CGS27023A, a matrix metalloproteinase inhibitor (Abstract). Proc Am Soc Clin Oncol 17: 213a, 1998
73. Igarashi N, Otani Y, Yokoyama T, Kimata M, Kubota T, Kitajima M: Combination therapy of matrix metalloproteinase inhibitor and cytotoxic agent reduces peritoneal dissemination of gastric carcinoma model in vivo (Abstract). Proc Am Assoc Can Res 39: 308, 1998
74. Bottomley KM, Johnson WH, Walter DS: Matrix metalloproteinase inhibitors in arthritis. J Enzyme Inhib 13: 79-101, 1998
75. Moldovan F, Pelletier J-P, Hambor J, Cloutier J-M, MartelPelletier J: Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep later of human arthritic cartilage in situ: in vitro mimicking effect by transforming growth factor beta. Arthritis Rheum 40: 1653-1661, 1997
76. Walakovits L, Moore V, Bhardwaj N, Gallick G, Lark M: Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum 35: 35-42, 1992
77. Zafarullah M, Pelletier J-P, Cloutier J-M, Martel-Pelletier J: Elevated metalloproteinase and tissue inhibitor of metalloproteinase mRNA in human osteoarthritic synovia. J Rheumatol 20: 693-697, 1993
78. Hembry R, Bagga M, Reynolds J, Hamblen D: Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. Ann Rheum Dis 54: 25-32, 1995
79. Bottomley K, Borkakoti N, Bradshaw D, Brown P, Broadhurst M, Budd J, Elliot L, Eyers P, Hallan T, Handa B, Hill C, James M.: Inhibition of bovine nasal cartilage degradation by selective matix metalloproteinase inhibitors. Biochem J 323: 483-488, 1997
80. Lewis E, Bishop J, Bottomley D, Bradshaw D, Brewster M, Broadhurst M, Brown P, Budd J, Elliott L, Greenham A, Johnson W, Nixon J.: Re-32-3555, an orally active collagenase inhibitor, prevents cartilage breakdown in vitro and in vivo. Brit J Pharm 121: 540-546, 1997
81. Brewster M, Lewis E, Wilson K, Greenham A, Bottomley K: Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum 41: 1639-1644, 1998
82. Wood N, Aitken M, Harris S, Kitchener S, McClelland G, Sharp S: The tolerability and pharmacokinetics of the cartilage protective agent (R032-3555) in healthy male volunteers (Abstract). Brit J Clin Pharm 42: 676P-677P, 1996
83. Lollini L, Haller J, Eugui E, Womble S, Martin R, Campbell J, Hendricks T, Broka C, Moskowitz R, Van Wart H, Caulfield J: Disease modification by RS-130830, a collagenase-3 selective inhibitor in experimental osteoarthritis (OA) (Abstract). Arthritis Rheum 40: 341, 1997
84. Macchiarini P, Fontanini G, Hardin M, Squartini F, Angeletti C: Relation of neovascularisation to metastasis of non-small cell lung cancer. Lancet 340: 145-146, 1992